Adriamycin in advanced urinary tract cancer.Experience in 42 patients and review of the literature
- 1 January 1977
- Vol. 39 (1) , 279-285
- https://doi.org/10.1002/1097-0142(197701)39:1<279::aid-cncr2820390143>3.0.co;2-k
Abstract
Forty-two patients with measureable, advanced, genito-urinary cancer received Adriamycin. Significant clinical responses (CR/PR) occurred in only five (14%) of 35 adequately treated patients. Four additional patients achieved a minimal response and four others showed stabilization of their disease for 4 to 9 months. Review of the literature suggests an overall response rate of 20%. Patients with a urinary diversion lived significantly longer (P 0.006) than patients who did not have this procedure (42.5 months vs 21.5 months). The need to define various patient characteristics in future chemotherapeutic trials in bladder cancer is discussed.This publication has 19 references indexed in Scilit:
- Adriamycin: A new effective agent in the therapy of disseminated sarcomasMedical and Pediatric Oncology, 1975
- AdriamycinAnnals of Internal Medicine, 1974
- Chemotherapy of Thyroid Cancer with AdriamycinNew England Journal of Medicine, 1974
- Phase II evaluation of adriamycin in human neoplasiaCancer, 1973
- Adriamycin and Daunomycin in the Treatment of Vesical and Prostatic Neoplasias. Preliminary ResultsPublished by Springer Nature ,1972
- Clinical Trials of AdriamycinPublished by Springer Nature ,1972
- Clinical Trials with Adriamycin. Results of Three-Years StudyPublished by Springer Nature ,1972
- Clinical trials with adriamycinCancer, 1971
- A generalized Wilcoxon test for comparing arbitrarily singly-censored samplesBiometrika, 1965
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958